[Newsdesk] Merck's alimatravir licensing deal receives mixed response

In July 2026, Merck announced licensing agreements with seven manufacturers for generic production of its HIV drug alimatravir. These agreements aim to increase the drug's availability. Despite this step, concerns remain regarding access to the medication and equity in its distribution. The response to these agreements is mixed, indicating different views on the adequacy of these measures. The licensing agreements represent a step toward improving HIV treatment availability, but questions about equal access remain unresolved.